PYXS Stock Analysis: Buy, Sell, or Hold?
PYXS - Pyxis Oncology, Inc. Common Stock
$2.63
-0.22 (-7.72%)
▼
5d:
+17.94%
30d:
+53.8%
90d:
+78.91%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When PYXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: PYXS is 12.9% above its trading range ($2.33). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: PYXS is 12.9% above its trading range ($2.33). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: PYXS is currently trading at $2.63, which is considered extended relative to its 30-day fair value range of $1.58 to $2.33.
Technical Outlook: Technically, PYXS is in a uptrend. The price is approaching resistance at $1.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 7.7% recently.
Market Sentiment: PYXS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.00 (+166.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PYXS is in a uptrend. The price is approaching resistance at $1.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 7.7% recently.
Market Sentiment: PYXS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.00 (+166.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.58 -
$2.33
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- BEARISH: Price significantly overextended (+12.9% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.7%)
- BULLISH: Trading 166.2% below Wall St target ($7.00)
Trading Range Analysis
30-Day Trading Range
$1.58 -
$2.33
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.60
Resistance Level
$1.88
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.17
Wall Street Target
$7.00
(+166.2%)
Share & Embed Analysis
Last updated: July 02, 2026 10:46 PM ET
Data refreshes hourly during market hours. Next update: 11:46 PM
Data refreshes hourly during market hours. Next update: 11:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PYXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 57 HOLD |
